PMC4426646_01
Contrast-enhanced computed tomography (CECT) of the abdomen at the time of admission (A) axial view; (B) coronal view showed multiple liver masses.
40364_2015_35_Fig1_HTML.jpg
PMC4426646_01_40364_2015_35_Fig1_HTML.jpg
Fig1
Contrast-enhanced computed tomography (CECT) of the abdomen (Figure 1A and B) revealed multiple irregular and nodular liver masses with a maximum of 13 cm in diameter on the right liver.
Histopathology of the liver tumor. (A) Hematoxylin and eosin (HE) staining, X400; (B) anti-CD20 staining, X400; (C) anti-CD79a staining, X400; (D) anti-CD10 staining, X400; (E) anti-bcl-2 staining, X400; (F) anti-CD3 staining, X400; (G) EBV-encoded small RNAs (EBER) by in situ hybridization (ISH), X400. Tumor cells are positive for CD20, CD79a and CD10 and negative for bcl-2, CD3 and EBER.
40364_2015_35_Fig2_HTML.jpg
PMC4426646_01_40364_2015_35_Fig2_HTML.jpg
Fig2
The tumor cells were positive for CD20 (Figure 2B), CD79a (Figure 2C) and CD10 (Figure 2D), and negative for bcl-2 (Figure 2E), CD3 (Figure 2 F), and EBV-encoded small RNAs (EBER) by in situ hybridization (ISH) (Figure 2G).
Three months after discontinuation of RA treatment, CECT of the abdomen demonstrated a remarkable regression of the liver masses.
40364_2015_35_Fig3_HTML.jpg
PMC4426646_01_40364_2015_35_Fig3_HTML.jpg
Fig3
Three months after discontinuation of RA treatment, the tumor masses dramatically regressed (Figure 3).